| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Deoxymicanolide (15.625-125 mg/L; measured every 2 hours) inhibited the growth of Ralstonia solanacearum race 4 in a concentration-dependent manner, and at high concentrations it could completely inhibit its growth[1]. Deoxymicanolide (125 mg/L; 2-24 hours) induced time-dependent ultrastructural damage in Ralstonia solanacearum race 4, including cell shrinkage, cytoplasmic leakage and abnormal cell morphology, and the cell epidermis was completely thickened after 24 hours[1]. Deoxymicanolide (62.5-125 mg/L; measured every 2 hours for 24 hours) significantly improved the phosphorus utilization of Ralstonia solanacearum race 4[1]. Deoxymicanolide (62.5-125 mg/L; measured every 5 hours) inhibited the activities of CAT, POD and SOD in Ralstonia solanacearum race 4, with SOD inhibition rates of 73.50% (62.5 mg/L) and 86.41% (125 mg/L) at 10 minutes [1]. Deoxymicanolide (62.5-125 mg/L; 24 hours) significantly induced the accumulation of ROS in Ralstonia solanacearum race 4 cells, with levels exceeding those induced by 340 mg/L H₂O₂ [1]. Deoxymicanolide (62.5-125 mg/L; 24 hours after treatment) increased the level of MDA in Ralstonia solanacearum race 4 cells, indicating that excessive ROS led to lipid peroxidation [1].
|
|---|---|
| ln Vivo |
Deoxymicanolide (10 mg/kg; orally) inhibited acetic acid-induced writhing response in a male Swiss mouse (20-25 g) pain model (inhibition rate of 67.3%) [2].
|
| Animal Protocol |
Animal/Disease Models:Swiss mice (male, 20-25 g) [2]
Doses: 10 mg/kg Route of Administration: Oral Experimental Results: Compared with the control group (26.0 writhing movements), acetic acid-induced writhing movements were reduced to 8.5, and the writhing response inhibition rate was 67.3%. |
| References |
| Molecular Formula |
C15H16O5
|
|---|---|
| Molecular Weight |
276.28
|
| CAS # |
23753-57-3
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
C=C1[C@]2([H])[C@](OC1=O)([H])C[C@]3([C@@](CCC4=C[C@@]2([H])OC4=O)([H])O3)C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6195 mL | 18.0976 mL | 36.1952 mL | |
| 5 mM | 0.7239 mL | 3.6195 mL | 7.2390 mL | |
| 10 mM | 0.3620 mL | 1.8098 mL | 3.6195 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
